Firibastat

Summary

Firibastat (CHEMBL4297511) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including hypertensive disorder and myocardial infarction.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 10
• Chemistry: 368.5 Da · C8H20N2O6S4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297511
Name	Firibastat
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	24851355
Molecular formula	C8H20N2O6S4
Molecular weight	368.5
InChIKey	HJPXZXVKLGEMGP-YUMQZZPRSA-N

SMILES: C(CS(=O)(=O)O)[C@@H](CSSC[C@H](CCS(=O)(=O)O)N)N

IUPAC name: (3S)-3-amino-4-[[(2S)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid

Also known as: Firibastat, Qgc-001, Qgc001, QGC001, RB-150, FIRIBASTAT

Patent coverage: 21 distinct patent families (45 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hypertensive disorder	3	MONDO:0005044	EFO:0000537
myocardial infarction	2	MONDO:0005068	EFO:0000612
heart failure	2	MONDO:0005252	EFO:0003144
essential hypertension	2	MONDO:0001134	MONDO:0001134
kidney failure	1	MONDO:0001106	EFO:1002048

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1	4
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04277884	PHASE3	COMPLETED	Firibastat in Treatment-resistant Hypertension
NCT04857840	PHASE3	TERMINATED	Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
NCT02322450	PHASE2	COMPLETED	Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
NCT02780180	PHASE2	TERMINATED	QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
NCT03198793	PHASE2	COMPLETED	Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
NCT03715998	PHASE2	COMPLETED	Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
NCT01900171	PHASE1	COMPLETED	Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
NCT01900184	PHASE1	COMPLETED	Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects
NCT03714685	PHASE1	COMPLETED	Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
NCT04792333	PHASE1	COMPLETED	Pharmacokinetics in End Stage Renal Disease Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).